Pseudohypoparathyroidism Type 1A with Normocalcaemia, due to the Novel C.389A>G Variant of Exon 5 of the Guanine Nucleotide-Binding Protein, α-Stimulating Gene.

J Bone Metab

Unit of Paediatric Endocrinology and Metabolism, Second Department of Paediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.

Published: February 2021

Pseudohypoparathyroidism type 1A (PHP1A) is a rare disease caused by molecular defects in the maternally-inherited allele of the guanine nucleotide-binding protein, α-stimulating (GNAS) gene. The GNAS gene encodes the stimulatory G-protein α-subunit that regulates production of the second messenger cyclic adenosine monophosphate. Heterozygous inactivating mutations in these specific loci are responsible for a spectrum of phenotypic characteristics of the disease, including clinical features of the Albright's hereditary osteodystrophy, due to resistance to parathyroid hormone (PTH). We report a case of PHP1A and explore the underlying novel point mutation of the GNAS gene that leads to an atypical PHP1A phenotype. A male patient with a round face, short stature, and brachydactyly accompanied by normocalcaemia and mild PTH resistance consulted at our center. The GNAS encoding region from the patient and both of his parents were amplified and sequenced directly in a sample of peripheral blood leukocytes. A novel c.389A>G point mutation in exon 5 of the GNAS gene, resulting in a p.Tyr130Cys peptidic chain change of the Gsα protein, detected in the proband, in heterozygous state. Sequencing of the GNAS gene from his parents did not reveal the c.389A>G mutation, confirming a de novo proband genotype. The maternal origin of the affected GNAS allele, along with mild PTH resistance, confirmed the PHP1A diagnosis. PHP1A, caused by inactivating GNAS mutations, presents a range of complex clinical phenotypes. The novel c.389A>G GNAS mutation presented in this case expands the spectrum of known PHP1A molecular defects and describes the associated phenotype.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973403PMC
http://dx.doi.org/10.11005/jbm.2021.28.1.85DOI Listing

Publication Analysis

Top Keywords

gnas gene
20
novel c389a>g
12
gnas
9
pseudohypoparathyroidism type
8
guanine nucleotide-binding
8
nucleotide-binding protein
8
protein α-stimulating
8
molecular defects
8
point mutation
8
mild pth
8

Similar Publications

Background: Gallbladder neuroendocrine carcinoma (NEC) represents a subtype of gallbladder malignancies characterized by a low incidence, aggressive nature, and poor prognosis. Despite its clinical severity, the genetic alterations, mechanisms, and signaling pathways underlying gallbladder NEC remain unclear.

Case Summary: This case study presents a rare instance of primary gallbladder NEC in a 73-year-old female patient, who underwent a radical cholecystectomy with hepatic hilar lymphadenectomy and resection of liver segments IV-B and V.

View Article and Find Full Text PDF

Background: Fibrous dysplasia (FD), caused by activating mutations of GNAS, is a skeletal disorder with considerable clinicopathological heterogeneity. Although prevalent mutations such as R201C and R201H dominate in FD, a limited number of rare mutations, including R201S, R201G, and Q227L, have been documented. The scarcity of information concerning these uncommon mutations motivates our investigation, seeking to enhance comprehension of this less-explored subgroup within FD.

View Article and Find Full Text PDF

Objective: To explore the clinical and genetic characteristics of two children diagnosed with two rare genetic diseases simultaneously.

Methods: Two children with comorbidity of two genetic diseases due to dual genetic mutations diagnosed at the Third Affiliated Hospital of Zhengzhou University respectively in May 2022 and March 2023 were selected as the study subjects. Clinical and genetic data of the two children were retrospectively analyzed.

View Article and Find Full Text PDF

Purpose: Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) trial, which was a multicenter, open-label, single-arm phase II study, showed a promisingly high interim clinical complete response (cCR) rate of 84.4% (38/45). In the present study, we aimed to identify potential tissue biomarkers for achieving cCR via BPT-ART.

View Article and Find Full Text PDF

Cell of origin and expression profiles of pseudomyxoma peritonei derived from the appendix.

Pathol Res Pract

December 2024

Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address:

Article Synopsis
  • Pseudomyxoma peritonei (PMP) is a rare condition linked to mucin-producing tumors, usually starting in the appendix, leading to mucin buildup in the abdomen.
  • Researchers conducted RNA-seq analysis on ten PMP cases and their healthy tissue to reveal 32 differently expressed genes, indicating that PMP tumors arise from goblet cells.
  • The study found significant associations between PMP tumors and important biological processes like epithelial-mesenchymal transition, angiogenesis, and inflammation, with further analysis highlighting distinct gene expressions in different PMP types, suggesting more aggressive traits in peritoneal mucinous adenocarcinomas (PMCA).
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!